



(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 38/43 (2006.01)
C12N 15/63 (2006.01) A61P 31/14 (2006.01)

(21) International Application Number:

PCT/SG2021/050155

(22) International Filing Date:

22 March 2021 (22.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202002623W 20 March 2020 (20.03.2020) SG

(71) Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).


(72) Inventors: KENG, Choong Tat; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome #02-01, Singapore 138672 (SG). CHU, Jang Hann; c/o National University of Singapore, MD4, Level 5, 5 Science Drive 2, Singapore 117597 (SG). CHEW, Wei Leong; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome #02-01, Singapore 138672 (SG). LEE, Ching Hua; c/o National University of Singapore, MD4, Level 5, 5 Science Drive 2, Singapore 117597 (SG).

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: MOLECULAR SYSTEMS AND THERAPIES USING THE SAME

FIG. 9



(57) Abstract: The present invention relates to molecular systems comprising an RNA-guided RNA-targeting effector protein, and one or more guide RNA molecule (gRNA). The present invention also relates to the use of such systems in treatment or prevention of disease caused by an RNA virus, including Enterovirus. In one embodiment, the RNA-guided RNA-targeting effector protein is Cas protein, e.g. Cas13d orthologue of *Ruminococcus flavefaciens* (CasRx), and the guide RNA molecule comprising a guide sequence as set forth in any one of SEQ NO: 1-6. In another embodiment, the disease is hand, foot and mouth disease (HFMD).

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*